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Abstract
Background: Mechanical ventilation can promote lung injury by triggering a pro-inflammatory response.
Macrolides may exert some immunomodulatory effects and have shown significant benefits over other antibiotics
in ventilated patients. We hypothesized that macrolides could decrease ventilator-induced lung injury.
Methods: Adult mice were treated with vehicle, clarithromycin or levofloxacin, and randomized to receive
mechanical ventilation with low (12 cmH2O, PEEP 2 cmH2O) or high (20 cmH2O, ZEEP) inspiratory pressures for
150 minutes. Histological lung injury, neutrophil infiltration, inflammatory mediators (NFκB activation, Cxcl2, IL-10)
and levels of adhesion molecules (E-selectin, ICAM) and proteases (MMP-9 and MMP-2) were analyzed.
Results: There were no differences among groups after low-pressure ventilation. Clarithromycin significantly
decreased lung injury score and neutrophil count, compared to vehicle or levofloxacin, after high-pressure
ventilation. Cxcl2 expression and MMP-2 and MMP-9 levels increased and IL-10 decreased after injurious ventilation,
with no significant differences among treatment groups. Both clarithromycin and levofloxacin dampened the
increase in NFκB activation observed in non-treated animals submitted to injurious ventilation. E-selectin levels
increased after high pressure ventilation in vehicle- and levofloxacin-treated mice, but not in those receiving
clarithromycin.
Conclusions: Clarithromycin ameliorates ventilator-induced lung injury and decreases neutrophil recruitment into
the alveolar spaces. This could explain the advantages of macrolides in patients with acute lung injury and
mechanical ventilation.
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Background
Severe cases of acute lung injury are related to high
morbidity and mortality rates. These cases often require
invasive ventilatory support, which increases the risk of
complications [1]. Among other effects, mechanical ven-
tilation superimposes a mechanical stress within the
lung tissue [2], and may induce an additional injury
(ventilator-associated lung injury, VALI). In patients with
the acute respiratory distress syndrome, protective venti-
latory strategies have demonstrated a reduction in mor-
tality [3], highlighting the relevance of this pathogenetic
mechanism. However, there are no universally applicable
ventilatory settings that minimize the risk of VALI in all
patients [4].
There are no pharmacological strategies that have been
successfully used to treat or prevent VALI. Recently, a sur-
vival benefit in patients receiving mechanical ventilation
and macrolide therapy has been reported [5]. Similarly,
several studies have shown better survival rates in patients
with pneumonia treated with macrolides [6], compared to
those receiving other antibiotics. These results have been
confirmed even in cases of macrolide-resistant bacteria [7]
and in ventilator-associated pneumonia [8].
The mechanisms responsible for these benefits of
macrolides are unknown. Macrolides exert some anti-
inflammatory effects including modulation of leukocyte
recruitment [9], a shift in cytokine release towards
* Correspondence: Guillermo.muniz@sespa.princast.es
1Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias,
Oviedo, Spain
2Departamento de Biología Funcional, Instituto Universitario de Oncología
del Principado de Asturias (IUOPA), Universidad de Oviedo, Oviedo, Spain
Full list of author information is available at the end of the article
© 2013 Amado-Rodríguez et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Amado-Rodríguez et al. Respiratory Research 2013, 14:52
http://respiratory-research.com/content/14/1/52
anti-inflammatory molecules [10] or inhibition of the
extracellular matrix remodeling by targeting matrix-
metalloproteases [11].
Inflammation is one of the key steps required for
ventilator-induced lung injury (VILI, the experimental
counterpart of VALI) [12] and different anti-inflammatory
drugs have shown a decrease in VILI [13,14]. Based on the
anti-inflammatory properties of macrolides, we hypothe-
sized that clarithromycin could exert some beneficial
effects in a model of VILI by attenuating the inflammatory
response. To test this hypothesis, we submitted mice
treated with vehicle, clarithromycin or levofloxacin to
different ventilatory strategies and studied the severity of
lung injury and the extent of the inflammatory response.
Finally, as macrolide treatment decreased leukocyte
infiltration, the steps needed for cell recruitment were
assessed.
Materials and methods
Animals
8–12 week-old C57/BL6 mice were used in all the experi-
ments. Mice were kept under specific pathogens-free
conditions, with full access to food and water, in 12-hour
light/dark cycles. The experimental protocol was approved
by the University Animal Research Ethics Committee.
Experimental model
Mice were randomly assigned to receive one of three treat-
ments previous to ventilation: Vehicle (Ringer’s lactate),
clarithromycin (50 mg/kg per dose) or levofloxacin (50 mg/
kg per dose). Two doses with a 12-hour interval between
them were administered intraperitoneally. It has been
reported that doses in the 25–100 mg/kg range result in
clinically achievable drug levels in humans [15,16]. One
hour after the second dose, mice were anesthetized with
intraperitoneal ketamine and xylazin, a tracheostomy was
performed, and they were connected to a mechanical
ventilator. The animals were randomized to receive low
(peak inspiratory pressure 12 cmH2O, PEEP 2 cmH2O,
respiratory rate 100/min) or high (peak inspiratory pres-
sure 20 cmH2O, PEEP 0 cmH2O, respiratory rate 50/
min) pressures, using an Evita 2 Dura ventilator (Dräger,
Lübeck, Germany). After 150 minutes of ventilation, a
laparotomy was performed, the aorta sectioned and the
animal sacrificed by exsanguination. Then the thorax was
opened and the lungs removed. The left lung was fixated
with intratracheal 4% formaldehyde, and immersed in
the same fixative. The right lung was frozen at −80°C for
subsequent analysis. In additional animals (n = 5 per
group), a bronchoalveolar lavage was performed and the
protein content of the bronchoalveolar lavage fluid
(BALF) measured (BCA protein assay, Pierce, USA).
Histological studies
After fixation, the left lung was included in paraffin, and
a standard hematoxilin-eosin staining was performed in
three lung sections, separated by 1 mm intervals. A previ-
ously described score was used to quantify the severity of
lung damage [17]. To measure the neutrophil infiltration
of lung tissue, additional sections were immunostained
using an anti-myeloperoxidase antibody (Thermo, USA).
The number of myeloperoxidase-positive cells in three
randomly chosen high-power fields per section was
counted and averaged. Activation of Nuclear factor κB
(NFκB) was measured by counting the percentage of posi-
tive nuclei in histological sections immunostained with an
anti-p65 antibody (Cell signaling, USA).
Biochemical measurements
The right lung was homogenized in a lysis buffer
(199 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA,
1% sodium deoxycholate, 1% Triton X-100, 0.25% SDS,
1 mM sodium orthovanadate) with a protease inhibitors
cocktail (Complete Mini, Roche, Switzerland). The sam-
ples were centrifuged and the supernatants collected and
stored. Protein content was measured using a BCA assay
(Pierce, USA).
Nuclear extracts from lung tissue were prepared as pre-
viously described [18]. Briefly, frozen tissues were homog-
enized in a cold buffer (10 mM Tris–HCl pH 8, 1.5 mM
MgCl2, 10 mM KCl, 1 mM DTT and protease inhibitor
cocktail), centrifuged and the pellets resuspended in the
same buffer with 0.1% Triton X-100. After incubation,
samples were centrifuged and the nuclear pellets
resuspended in a buffer containing 20 mM Tris pH8, 25%
glycerol, 0.4 M NaCL, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 mM DTT and protease inhibitor cocktail. After incu-
bation, the nuclear extracts were finally centrifuged and
the supernatants collected and frozen at −80°C.
Gene expression was studied by quantitative PCR as de-
scribed [19]. Total RNA was extracted from tissue using
Trizol (Sigma, Poole, UK) and isopropanol precipitation.
Using this RNA, cDNA was synthesized (Enhanced avian
HS RT-PCR kit, Sigma, Poole, UK) and quantitative real
time PCR carried out in triplicate for each sample. Expres-
sion of Cxcl2 and beta-actin (Actb, as a loading control)
was measured using Taqman probes (Mm00436450_m1
and 4352341E respectively, Applied Biosystems, USA).
Relative expression was computed according to manufac-
turer’s instructions.
For western blotting assays, samples were loaded in a
10% SDS-polyacrilamide gel and electrophoresed. The pro-
teins were then transferred to a nitrocellulose membrane
and incubated with primary antibodies against p65 (Abcam,
UK), E-selectin (Abcam, UK), Intercellular adhesion
molecule-1 (ICAM-1, Abcam, UK) or beta-actin (Santa
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Cruz Biotechnologies #SC1616, USA). The binding of pri-
mary antibodies was detected by using a peroxidase-linked
secondary antibody and a chemoluminiscent reaction in a
LAS-3000 camera (Fujifilm Life Science, USA). Actin was
used as loading control.
Matrix metalloproteinases (MMP) -2 and −9 were mea-
sured by gelatin zymography, as previously described [20].
IL-10 was quantified using an ELISA (eBioscience,
San Diego, USA), following manufacturer’s instructions.
Statistical analysis
All the results are expressed as mean ± SEM. Differences
among groups were evaluated using an ANOVA, including
treatment and ventilatory strategy as factors. Paired post-hoc
Figure 1 Lung injury after mechanical ventilation. Structural lung injury increased with high-pressure ventilation in vehicle- and levofloxacin-
treated animals, but not in mice receiving clarithromycin (A). Alveolocapillary permeability, assessed by measurement of protein content in
bronchoalveolar lavage fluid (BALF), increased after high-pressure ventilation irrespective of the treatment (B). Neutrophil recruitment increased
after high-pressure ventilation in vehicle- and levofloxacin-treated animals. However, clarithromycin-treated animals showed no differences in
neutrophil counts compared to mice ventilated with low pressures (C). Representative sections are shown in panel D. *p < 0.05 in post-hoc tests
compared to low-pressure ventilated counterparts.
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tests were done using Bonferroni’s correction when appro-
priate. A p value lower than 0.05 was considered significant.
Results
60 animals were included in the study (8 mice/treatment
group received low-pressure ventilation and 12 mice/
treatment group received high-pressure ventilation). In 30
additional animals (5 per group), a BALF was performed
at the end of the experiment. All the animals survived the
experimental protocol.
Clarithromycin ameliorates ventilator-induced lung injury
First, tissue injury was evaluated in histological sections
(Figure 1A). Mechanical ventilation using low pressures
and PEEP caused no histological injury within the lungs in
any of the treatment groups. As expected, ventilation
Figure 2 Inflammatory response with high-pressure ventilation. High pressure ventilation results in an increase in the activation of NFκB,
measured as the percentage of p65 positive nuclei (A) or as the levels of p65 protein content in nuclear extracts (B). Both clarithromycin and
levofloxacin blocked this activation. Panel C shows representative p65-immunostained sections and western blots of nuclear extracts. Some
positive nuclei are shown (arrowheads). Cxcl2 expression (D) and interleukin-10 levels were measured (E). There was a significant increase in Cxcl2
expression and a slight decrease in IL-10 levels with injurious ventilation in all treatment groups. *p < 0.05 in post-hoc tests compared to low-
pressure ventilated counterparts.
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using high pressures and ZEEP was related to a significant
increase in the lung injury score due to septal thickening
and inflammatory infiltration. A similar increase was ob-
served in vehicle- and levofloxacin-treated animals. How-
ever, clarithromycin-treated mice developed only a mild
lung injury after ventilation.
Alveolocapillary permeability was assessed by measure-
ment of protein content in BALF (Figure 1B). High-
pressure ventilation increased the protein abundance, with
no differences among genotypes.
Neutrophilic infiltration is one of the hallmarks of
ventilator-induced lung injury. To confirm the decrease in
inflammatory infiltrates observed in the hematoxylin-
eosin-stained sections, an immunohistochemical study
was performed. The amount of myeloperoxidase-positive
cells (Figure 1C) was similar among the three groups of
low-pressure ventilation. Neutrophil counts increased
after high-pressure ventilation in vehicle and levofloxacin-
treated animals. However, the number of neutrophils
in clarithromycin-treated mice after VILI was similar to
the cell counts observed after low-pressure ventilation.
Figure 1D shows representative sections of each experi-
mental group.
Mechanisms of decreased neutrophilic infiltration
As the decreased neutrophilic count was the main differ-
ence among the three treatment groups, we focused on
the steps of leukocyte recruitment. First, we studied acti-
vation of the inflammatory response by measuring the
nuclear translocation of p65, a critical component of the
NFκB pathway (Figure 2A-C). Injurious ventilation re-
sults in a highly significant increase in the percentage of
p65 positive nuclei. However, levels of NFκB activation
in clarithromycin- and levofloxacin-treated mice venti-
lated using high pressures were similar to their counter-
parts ventilated with low pressures. To confirm this
finding, we measured levels of p65 in nuclear extracts.
In line with the immunohistochemical findings, there was
a lower p65 abundance in nuclei from clarithromycin-
and levofloxacin-treated animals after injurious ventilation
(Figure 2B). Panel 2C shows positive nuclei in all the
Figure 3 Changes in adhesion molecules. Mechanical ventilation using high pressures increased the levels of E-selectin (A) and ICAM-1 (B) in
lung tissue homogenates. Clarithromycin dampened the increase in E-selectin after VILI. Representative western blots are shown in panel C.
*p < 0.05 in post-hoc tests compared to low-pressure ventilated counterparts.
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experimental groups and a representative western blot of
nuclear extracts.
Chemokines are inflammatory mediators involved in
neutrophil recruitment. Expression of Cxcl2 gene (corre-
sponding to the chemokine MIP-2, the murine ortholog
of IL-8) was measured in all the experimental groups.
Mechanical ventilation increased its expression, but there
were no significant differences among genotypes
(Figure 2D). Additionally, we measured the levels of IL-10,
an anti-inflammatory cytokine that could decrease neutro-
phil recruitment (Figure 2E). Ventilator-induced lung injury
decreased IL-10 levels in lung homogenates compared to
low-pressure ventilation groups, but there were no differ-
ences caused by treatment.
The next step for cell recruitment is the attachment of
neutrophils to the endothelium to promote migration, so
we measured E-selectin and ICAM-1 expression in lung ho-
mogenates (Figure 3). E-selectin levels were similar among
groups after low-pressure ventilation, and increased after
VILI in vehicle- and levofloxacin-treated mice. However,
clarithromycin treatment dampened this increase in expres-
sion and protein levels in this group were similar to those
found in animals ventilated with low pressure (Figure 3A).
ICAM-1 increased in all the groups after injurious ven-
tilation with no differences among treatment groups
(Figure 3B). Panel 3C shows representative western blots.
Finally, we measured matrix metalloproteinases
(Figure 4A), as its activity is required for the digestion
of the extracellular fibers during cell migration. Matrix-
metalloproteinase-9 is a gelatinase released mainly by
neutrophils after activation. High-pressure ventilation in-
creased MMP-9 levels in lung homogenates. Interestingly,
levofloxacin-treated animals showed higher levels of
MMP-9, irrespective of the ventilatory settings (Figure 4B).
Matrix-metalloproteinase 2, which is a ubiquitous gelatinase,
increased after VILI, but without differences among treat-
ment groups (Figure 4C).
Discussion
Our results show that pretreatment with clarithromycin
ameliorates ventilator induced lung injury and decreases
the lung neutrophilic infiltrate. This effect is related to a
decrease in NFκB activity and E-selectin levels, that
could be the mechanisms responsible for the decreased
leukocyte recruitment.
Mechanical ventilation can induce or aggravate lung
injury by a multifactorial mechanism, in which deform-
ation of lung tissue triggers a complex biological re-
sponse. Inflammation, extracellular matrix remodeling
and different types of cell death have been described in
response to mechanical ventilation [21]. Among these,
alveolar inflammation with neutrophilic infiltration has
been widely studied [22]. Different strategies aimed to
decrease the polymorphonuclear infiltration within the
lung have been demonstrated effective to decrease
ventilator-induced lung injury [23]. Our results show a
decreased neutrophilic infiltration in clarithromycin-
treated animals, which could be the mechanism respon-
sible for the beneficial effect of this macrolide. However,
we did not find an improvement in alveolocapillary per-
meability. It has been proposed that the mechanisms
Figure 4 Matrix metalloproteinase activity. Both MMP-9 (A) and
MMP-2 (B) increased in all the experimental groups submitted to
high-pressure ventilation. MMP-9 levels were higher in levofloxacin-
treated animals, compared to the other treatment groups and
irrespective of the ventilatory strategy. A representative zymography
is shown in panel (C).
Amado-Rodríguez et al. Respiratory Research 2013, 14:52 Page 6 of 9
http://respiratory-research.com/content/14/1/52
that promote edema and cell infiltration could be inde-
pendently regulated [24,25].
Macrolides are a family of antibiotics with immuno-
modulatory properties. Several studies have identified
multiple mechanisms by which macrolides exert their
anti-inflammatory effects. Using different models of
acute lung injury (including LPS inhalation and bleo-
mycin instillation), a decrease in neutrophilic lung infil-
tration has been demonstrated in clarithromycin-treated
animals [26,27]. This effect could be mediated by several
mechanisms. Activation of the NFκB pathway is one of
the critical steps during a proinflammatory response.
Our immunohistochemical findings show this activation
to occur in isolated cells that could correspond to infil-
trating leukocytes, although the lack of double immuno-
staining precludes any firm conclusion. It has been
reported that both macrolides [28] and quinolones [29]
may block NFκB activation, resembling our own results.
However, we did not find any differences in Cxcl2 expres-
sion that could explain the decreased neutrophilic infil-
trates in animals receiving clarithromycin. Different
intracellular mechanisms other than NFκB (such as MAP
kinases) could be responsible for this increased chemokine
expression [30].
Additionally, macrolides may decrease the levels of ad-
hesion molecules such as ICAM-1, VCAM, E-selectin and
P-selectin [31]. The increase in adhesion molecules during
VILI has been described previously [32], and is needed for
the attachment of neutrophils to the endothelium as an
initial step for cell migration. Our results fit with these,
showing an increase in ICAM-1 and E-selectin during
VILI. However, mice treated with clarithromycin showed
significantly lower levels of E-selectin after VILI. Lastly, al-
though macrolides may also decrease MMP expression
[11], we have found no differences in MMP-2 or −9 in our
experimental model.
A wide range of strategies aimed to the limitation of
the inflammatory response has shown positive results in
models of VILI [13,14]. Although none of them have
been translated to the clinical practice yet, a pharmaco-
logical strategy to ameliorate VALI could be a promising
approach in ventilated patients.
Our results may have clinical implications that must be
discussed. First, they could explain the beneficial effects
observed in ventilated, macrolide-treated patients in both
experimental models and the clinical practice. Moreover,
clarithromycin (and probably other macrolides) could be
used in ventilated patients only for its immunomodulatory
effects. The recent finding of a decreased mortality in
patients with acute lung injury receiving macrolide ther-
apy [5] opens this possibility, as the benefit was independ-
ent of other variables such as severity scores, tidal volume
or organ failures. The positive results observed in our
study correlate with these studies showing an improved
outcome in cases of pneumonia and/or septic shock re-
ceiving these drugs [8,33], and even with the use of
macrolides to limit the inflammatory response in chronic
lung diseases [34].
Our methodology has some limitations that must be
clarified before any firm recommendation on macrolide
use, especially with indications other than their anti-
microbial properties. First, although widely used and ac-
cepted [35], our experimental model has no clear clinical
correlate. The pressures and volumes used to induce
VILI are higher than those used in the clinical practice.
This was done to increase the signal-to-noise ratio, and
precludes a direct translation of the findings. Second, no
anti-inflammatory strategy has been shown effective to
decrease mortality in patients with acute lung injury and
mechanical ventilation. There are increasing evidences
showing that inflammation is needed for later tissue re-
pair [36-39]. In this sense, preventive or early inhibition
of the inflammatory response may be beneficial, but a
later inhibition could compromise lung healing. There-
fore, these strategies should be viewed with caution and
carefully studied. Third, use of antibiotics may have a
profound impact on microbial populations and their
sensitivities, and the benefits and risks of their applica-
tion must include an epidemiologic approach before a
systematic indication. Finally, we cannot discard other
macrolide-triggered mechanisms, which could be re-
sponsible for the beneficial results shown here or even
other unwarranted effects.
Conclusions
In spite of these limitations, we may conclude that
clarithromycin decreases VILI possibly by dampening
the lung leucocyte infiltration. A decrease in NFκB acti-
vation and E-selectin expression could be the molecular
mechanisms responsible for this effect. Although these
results are subjected to the common limitations of pre-
clinical studies, they give additional support to the use
of macrolides in mechanically ventilated patients and
open the possibility of a new therapeutic approach to
limit ventilator-associated lung injury.
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